文献速递病毒性肝炎

GLS4在慢性乙肝患者中的抗病毒活性与药代动力学

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection.
PubMed 文献 · Clin Infect Dis · 2021-01-01

GLS4是一种I类HBV衣壳组装调节剂。这项双盲随机对照1b期研究纳入24例慢性乙肝患者,随机接受28天GLS4(120或240mg)联合利托那韦或恩替卡韦治疗。结果显示120mg GLS4联合利托那韦可耐受并具有抗病毒活性,但HBV DNA下降幅度低于恩替卡韦。

要点

  • GLS4 120mg联合利托那韦治疗28天可耐受并具有抗病毒活性。
  • GLS4谷浓度约为90%有效浓度的3.7-3.9倍。
  • GLS4组HBV DNA下降幅度低于恩替卡韦组。

核心结论

  • 120mg GLS4联合利托那韦治疗在慢性乙肝患者中可耐受并具有抗病毒活性。

研究设计与样本

  • 双盲、随机、平行、恩替卡韦对照的1b期研究,纳入24例慢性乙肝患者,按1:1:1随机接受28天GLS4 120mg联合利托那韦100mg、GLS4 240mg联合利托那韦100mg或恩替卡韦治疗,随访40天。

主要发现

  • A、B、C组分别有2、3、3例出现丙氨酸氨基转移酶flare,分别导致1、2、1例退出。
  • GLS4平均谷浓度为205-218 ng/mL,约为90%有效浓度(55.8 ng/mL)的3.7-3.9倍,蓄积率1.1-2.0。
  • A、B、C组治疗28天后HBV DNA平均下降分别为-1.42、-2.13、-3.5 log10 IU/mL。
  • A、B、C组HBsAg平均下降分别为-0.06、-0.14、-0.33 log10 IU/mL。
  • A、B、C组前基因组RNA平均下降分别为-0.75、-1.78、-0.96 log10 copies/mL;HBcAg平均下降分别为-0.23、-0.5、-0.44 log10 U/mL。

临床怎么用

  • GLS4 120mg联合利托那韦可作为慢性乙肝治疗的候选方案,但需进一步研究验证。

局限性

  • 样本量小(24例),随访期短(40天),抗病毒活性低于恩替卡韦。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator (class I) that can inhibit HBV replication by interfering with the assembly and disassembly of HBV nucleocapsid. Here, we evaluated its antiviral activity, pharmacokinetics, and tolerability in a double-blind, randomized, parallel, entecavir-controlled study. METHODS: Twenty-four patients with chronic HBV were randomized to receive a 28-day course of GLS4 (120 or 240 mg) and ritonavir (100 mg) combination (cohorts A and B, respectively) or entecavir treatment (cohort C) at a 1:1:1 ratio. Patients were followed up for 40 days in a phase 1b study. RESULTS: The GLS4/ritonavir combination was a tolerated combination for the treatment of chronic HBV infection. A total of 2, 3, and 3 subjects presented with alanine aminotransferase flare in cohorts A, B, and C, respectively. This contributed to the withdrawal of 1, 2, and 1 patient from cohorts A, B, and C, respectively. The mean Ctrough of GLS4 was 205-218 ng/mL, which was approximately 3.7-3.9 times the 90% effective concentration (55.8 ng/mL), with a lower accumulation (accumulation rate, 1.1-2.0). In cohorts A, B, and C, the mean declines in HBV DNA after 28 days of treatment were -1.42, -2.13, and -3.5 log10 IU/mL; in hepatitis B surface antigen were -0.06, -0.14, and -0.33 log10 IU/mL; in pregenomic RNA were -0.75, -1.78, and -0.96 log10 copies/mL; and in hepatitis B core antigen were -0.23, -0.5, and -0.44 log10 U/mL, respectively. CONCLUSIONS: Treatment with 120 mg GLS4 was tolerated and had antiviral activity in patients with chronic HBV infection. CLINICAL TRIALS REGISTRATION: Chinese Clinical Trial Registry; CTR20160068. http://www.chinadrugtrials.org.cn.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhang H, Wang F, Zhu X, et al. Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. Clin Infect Dis. 2021. PMID: 32649736. doi:10.1093/cid/ciaa961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。